An open-label, dose-escalating clinical Phase 1/2a trial evaluating the safety, pharmacokinetics (PK), and antitumor activity of modified allogeneic C.I.K. cells administered to pediatric and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)

Trial Profile

An open-label, dose-escalating clinical Phase 1/2a trial evaluating the safety, pharmacokinetics (PK), and antitumor activity of modified allogeneic C.I.K. cells administered to pediatric and adult patients with relapsed or refractory acute lymphoblastic leukemia (ALL)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 21 Sep 2017

At a glance

  • Drugs CIK-CAR-CD19 immunotherapy (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Sep 2017 New trial record
    • 18 Sep 2017 This trial is sponsored by Fondazione Matilde Tettamanti and supported in part by Formula in accordance with the Italian/EU regulations and will be conducted at the MBBM Foundation/San Gerardo Hospital and the Azienda Ospedaliera Papa Giovanni XXIII as reported in a media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top